He says he likes the chances of our heart failure drug but would buy the safer AMGN over CYTK. With one company's market cap more than 360 times that of the other, I find it hard to imagine that is the correct play on omecamtiv mecarbil, or this technology in general. If one is risk adverse, buy a smaller stake.
If one is interested in playing AMGN's pipeline (I am not) then buy AMGN. But the video is about heart failure treatment.
AMGN roughly doubled in 2 years. CYTK doubled in 2 months. Sure we are in pull back mode now because of misinterpreted trial results from the IV ATOMIC dose discovery trial, but now we know what the dose is. That was why the trial was done. Results were expected. I have no crystal ball, thats obvious, but a great deal of cash can be made on the foolishness and ignorance of others.
That's why I own both. A larger stake in AMGN for a prolonged 5-10 year investment, and a smaller in CYTK for the fun growth. Now if AMGN buys up CYTK they're pretty much just paying me a nice dividend!